Albert David Limited
NSE: ALBERTDAVD · Pharmaceuticals · sector
₹777.10NSE close 2026-10-26
Key numbers
Market cap₹444 cr
Price₹777.10
52w high / low₹932 / ₹580
P/E19.7xSector median 27.9x
P/B1.1xSector median 2.9x
Book value₹686.0
Dividend yield0.65%Sector median 0.48%
ROE5.8%Sector median 11.7%
ROCE7.3%Sector median 12.3%
OPM7.3%Sector median 14.0%
Debt / equity0.07xSector median 0.16x
EV/EBITDA8.0xSector median 18.6x
Interest cover11.8x
Current ratio3.24x
Sales growth 3y-0.8%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.08x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹258 cr vs borrowings ₹28 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 11.8x in the last 12 months.
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY25, FY24, FY23).
- Net loss in 4 of the last 8 quarters.
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 59% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹777.10 on 2026-10-26: -16.6% from the 52-week high, +34.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,491.20 · low ₹616.20
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 98 | 83 | 75 | 71 | 87 | 90 | 86 | 101 |
| EBITDA | 6 | 1 | -5 | -11 | 3 | 11 | 3 | 11 |
| OPM % | 6.3% | 0.8% | -6.3% | -15.1% | 2.9% | 12.0% | 3.2% | 10.5% |
| Other income | 21 | -9 | -5 | 22 | -2 | 12 | -25 | 28 |
| Net profit | 18 | -9 | -10 | 8 | -3 | 15 | -21 | 32 |
| EPS (₹) | 31.67 | -16.45 | -18.10 | 13.91 | -5.79 | 26.81 | -37.56 | 56.07 |
| Revenue YoY | -11.4% | +8.2% | +14.6% | +43.6% | ||||
| Profit YoY | -118.3% | – | – | +303.0% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 314 | 342 | 362 | 346 | 334 | 364 |
| EBITDA | 41 | 44 | 47 | 3 | 5 | 27 |
| Net profit | 35 | 36 | 75 | 17 | -1 | 23 |
| EPS (₹) | 61.78 | 63.39 | 132.15 | 30.14 | -2.62 | 39.53 |
| Revenue growth | +8.9% | +6.1% | -4.6% | -3.5% | +11.4% | |
| Profit growth | +2.6% | +108.5% | -77.2% | -108.7% | +258.5% | |
| Dividend / share (₹) | 6.00 | 9.00 | 9.00 | 11.50 | 5.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -0.8% | +6.2% | +11.4% |
| Net profit | – | – | +258.5% |
| EPS | – | – | – |
| Share price | – | -25.1% (2y) | -1.7% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 312 | 383 | 392 | 392 |
| Borrowings | – | 5 | 2 | 10 | 28 |
| Cash & equivalents | – | 192 | 285 | 244 | 258 |
| Total assets | – | 423 | 498 | 511 | 519 |
| Fixed assets | – | 78 | 82 | 98 | 99 |
| Capital work in progress | – | 3 | 7 | 2 | 21 |
| Investments | – | 26 | 19 | 1 | 3 |
| Receivables | – | 30 | 29 | 27 | 34 |
| Inventory | – | 51 | 44 | 64 | 58 |
| Payables | – | 32 | 34 | 38 | 33 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 40 | 11 | 46 | -28 | -8 |
| Cash from investing | -40 | -5 | -33 | 23 | -4 |
| Cash from financing | -5 | -6 | -8 | 0 | 12 |
| Capex | 11 | 5 | 11 | 15 | 29 |
| Free cash flow | 29 | 5 | 35 | -43 | -37 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 11.6% | 19.7% | 4.4% | -0.4% |
| ROCE % | – | 16.2% | 25.3% | 6.4% | 0.8% |
| Debtor days | – | 32 | 30 | 29 | 37 |
| Inventory days | – | 150 | 126 | 201 | 187 |
| Payable days | – | 95 | 98 | 118 | 104 |
| Cash conversion cycle (days) | – | 87 | 58 | 112 | 120 |
| Working capital days | – | 219 | 274 | 264 | 283 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 62.24% |
| FIIs | 0.60% |
| DIIs | 1.64% |
| of which Mutual funds | 0.01% |
| of which Insurance | 1.61% |
| Public (non-institutions) | 35.53% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 62.13% | 62.24% | 62.24% | 62.24% | 62.24% | 62.24% | 62.24% | 62.24% |
| Promoter group | % |
|---|---|
| Kothari Investment and Industries Private Limited | 41.36% |
| Anand Vardhan Kothari | 9.93% |
| M D Kothari and Company Limited | 6.92% |
| Kothari Phytochemicals & Industries Limited | 1.74% |
| Arun Kumar Kothari | 1.70% |
| Prabhawati Devi Kothari | 0.31% |
| Paramsukhdas Suganchand HUF (Karta - Arun Kumar Kothari) | 0.26% |
| Vedika Kothari | 0.03% |
| Public holders above 1% | % |
|---|---|
| General Insurance Corporation of India | 1.61% |
| Vikabh Securities PVT. Ltd. | 1.00% |
12,709 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ALBERTDAVD | ₹444 cr | 19.7x | 1.1x | 5.8% | 7.3% | 7.3% | -0.8% | 0.65% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-30 | Dividend | Dividend - Rs 5 Per Share |
| 2025-07-25 | Dividend | Dividend - Rs 5 Per Share |
| 2024-08-02 | Dividend | Dividend - Rs 11.50 Per Share |
| 2024-08-02 | Other | Annual General Meeting |
| 2023-08-03 | Other | Annual General Meeting |
| 2023-08-03 | Dividend | Dividend - Rs 9 Per Share |
| 2022-08-01 | Dividend | Annual General Meeting/Dividend - Rs 9 Per Share |
| 2021-09-06 | Dividend | Dividend - Rs 6 Per Share |
| 2021-09-06 | Other | Annual General Meeting |
| 2020-09-16 | Other | Annual General Meeting |
| 2020-03-13 | Dividend | Interim Dividend - Rs 7 Per Share |
| 2019-08-01 | Dividend | Annual General Meeting/Dividend - Rs 6 Per Share |
| 2018-08-24 | Dividend | Annual General Meeting/Dividend- Rs 5.50 Per Share |
| 2017-09-01 | Dividend | Annual General Meeting/Dividend - Rs 5.50 Per Share |
| 2016-09-01 | Other | Annual General Meeting |
Documents
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Annual report FY21
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ALBERTDAVD |
| BSE code | 524075 |
| ISIN | INE155C01010 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.